Wanbury Shareholders Approve All Resolutions at 38th AGM
Wanbury Ltd 路 Annual General Meeting 路 25 Sept 2026, 9:38 pm
Wanbury Shareholders Approve All Resolutions at 38th AGM Wanbury Limited announced the results of its 38th AGM held on 24th Sep'26. Shareholders approved all four resolutions with requisite majority, achieving a 43.91% overall voting turnout (15,354,856 total votes polled across 34,966,928 shares). Key approvals include the adoption of FY26 audited financial statements (~100% votes in favour), the re-appointment of retiring director Mr. K. Chandran (~100% in favour), the ratification of cost auditor remuneration for FY27 (~100% in favour), and the special resolution for re-appointing Whole-time Director Mr. Mohan Kumar Rayana beyond age 70 (99.94% overall approval).
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. 路 30 Oct 2026
